These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16739326)

  • 1. Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group.
    Shimane Breast Cancer Study Group
    Anticancer Res; 2006; 26(1B):591-7. PubMed ID: 16739326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
    Tominaga T; Koyama H; Toge T; Miura S; Sugimachi K; Yamaguchi S; Hirata K; Monden Y; Nomura Y; Toi M; Kimijima I; Noguchi S; Sonoo H; Asaishi K; Ikeda T; Morimoto T; Ota J; Ohashi Y; Abe O
    J Clin Oncol; 2003 Mar; 21(6):991-8. PubMed ID: 12637462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of complications in a randomized controlled study on multimodality therapy for patients following breast-conserving surgery: Kansai Breast Cancer Radiotherapy Research Group (5'-KBR)].
    Hiraoka M; Koyama H; Inoue T; Kono N; Kono M; Kodama H; Inaji H; Sako M; Suzuki R;
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1153-60. PubMed ID: 12145995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
    Noguchi S; Kim HJ; Jesena A; Parmar V; Sato N; Wang HC; Lokejaroenlarb S; Isidro J; Kim KS; Itoh Y; Shin E
    Breast Cancer; 2016 Sep; 23(5):771-9. PubMed ID: 26350351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.
    Baum M; Hackshaw A; Houghton J; Rutqvist ; Fornander T; Nordenskjold B; Nicolucci A; Sainsbury R;
    Eur J Cancer; 2006 May; 42(7):895-904. PubMed ID: 16545560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant chemotherapy after curative resection for gastric cancer-5'-DFUR + cisplatin vs 5'-DFUR].
    Fujitani K; Kobayashi K; Tamaki Y; Tsujinaka T; Hirao M
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):61-5. PubMed ID: 11816479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
    Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
    Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen].
    Tohma H; Noshiro H; Hachiya Y; Akashi Y; Miyoshi A
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1267-9. PubMed ID: 8031170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C).
    Andersen J; Kamby C; Ejlertsen B; Cold S; Ewertz M; Jacobsen EH; Philip P; Møller KA; Jensen D; Møller S
    Acta Oncol; 2008; 47(4):718-24. PubMed ID: 18465340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer.
    Tsuruta K; Okamoto A; Egawa N; Kamisawa T; Karasawa K; Takahashi T
    J Surg Oncol; 2001 Nov; 78(3):202-7. PubMed ID: 11745808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A histological observation after a short-term administration of 5'-DFUR and tamoxifen in patients with advanced breast cancer].
    Yamamoto T; Funatsuka M; Naitoh A; Yano S; Tamura K
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):2071-4. PubMed ID: 8215485
    [No Abstract]   [Full Text] [Related]  

  • 16. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
    Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
    Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].
    Mitsuyama S; Nomura Y; Ohno S; Miyauchi M; Yamamoto N; Kimura T; Saku M; Miura S; Yoshikawa N; Tsujinaka T; Koh J; Ishida T; Abe O; Ohashi Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2071-7. PubMed ID: 16352931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
    Ota J; Taguchi T; Sakai K; Irie K; Terasawa T; Shimoyama T; Kawahara T; Okumura T; Yamamoto M; Yasutake K
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1279-84. PubMed ID: 1386974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.